News and Announcements
CASE REPORT
E-cadherin-positive and strong P53-positive acute erythroleukemia in an elderly man: A case report
Yasuhiro Kazuma1 ,
Yutaka Shimazu1,2 ,
Keisuke Shindo1 ,
Naoyuki Anzai1 ,
Miyako Kobayashi1 ,
Satoko Mibayashi3 ,
Shinsaku Imashuku1,4*
Show Less
1
Department of Hematology, Uji-Tokushukai Medical Center, Uji, Kyoto,
Japan
2
Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto,
Japan
3
Department of Diagnostic Pathology, Uji-Tokushukai Medical Center, Uji, Kyoto,
Japan
4
Department of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji, Kyoto,
Japan
Tumor Discovery, 3275 https://doi.org/10.36922/td.3275
Submitted: 26 March 2024 | Accepted: 12 June 2024 | Published: 4 September 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract
Acute erythroleukemia (FAB M6), a rare form of acute myeloid leukemia, consists of two subtypes: M6a-erythroid/myeloid leukemia and M6b-pure erythroid leukemia (PEL). The diagnosis of PEL is often difficult due to the negativity of classical erythroid cell markers. Recently, an epithelial calcium-dependent cell adhesion protein (E-cadherin) has been identified as a marker of immature erythroid precursors. Here, we report an elderly case of PEL in which E-cadherin positivity and strong P53 positivity were the key clues for diagnosis. The patient was treated with a daunomycin/Ara-C regimen followed by a venetoclax/azacitidine regimen but responded to neither treatment.
Keywords
Acute erythroleukemia
Pure erythroid leukemia
E-cadherin
P53
Funding
None.
Conflict of interest
The authors declare no conflicts of interest.
References
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405. doi: 10.1182/blood-2016-03-643544
- Weinberg OK, Arber DA. Erythroleukemia: An update. Curr Oncol Rep. 2021;23(6):69. doi: 10.1007/s11912-021-01060-8
- Reichard KK, Tefferi A, Abdelmagid M, et al. Pure (acute) erythroid leukemia: Morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases. Blood Cancer J. 2022;12(11):147. doi: 10.1038/s41408-022-00746-x
- Ohgami RS, Chisholm KM, Ma L, Arber DA. E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. Am J Clin Pathol. 2014;141(5):656-664. doi: 10.1309/AJCP8M4QQTAZPGRP
- Tamura A, Uemura S, Saito A, et al. Congenital immature pure erythroid leukemia with E-cadherin expression. Int J Hematol. 2017;106(5):711-717. doi: 10.1007/s12185-017-2248-7
- Caldwell I, Ruskova A, Royle G, Liang J, Bain BJ. Pure erythroid leukemia: The value of E-cadherin in making the diagnosis. Am J Hematol. 2019;94(6):726-727. doi: 10.1002/ajh.25437
- Jakobiec FA, Wolkow N, Zakka FR, Rubin PAD. Myeloid sarcoma with megakaryoblastic differentiation arising in the conjunctiva. Ocul Oncol Pathol. 2019;5(1):28-35. doi: 10.1159/000488057
- Iacobucci I, Wen J, Meggendorfer M, et al. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019;51:694-704. doi: 10.1038/s41588-019-0375-1
- Strouboulis J. Erythroleukemia: All roads lead to GATA1? Blood. 2020;136(6):648-649. doi: 10.1182/blood.2020006107
- Kallakury BV, Figge J, Ross JS, Fisher HA, Figge HL, Jennings TA. Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol. 1994;25(1):92-97. doi: 10.1016/0046-8177(94)90177-5
- Limani R, Lež C, Krušlin B. Exploring the relationship between E-cadherin and β-catenin cell adhesion proteins and periacinar retraction clefting in prostatic adenocarcinoma. Diagnostics (Basel). 2024;14(5):511. doi: 10.3390/diagnostics14050511
- Domingo-Claros A, Larriba I, Rozman M, et al. Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Haematologica. 2002;87(2):148-153.
- Takeda J. Molecular pathogenesis and therapeutic targets in acute erythroid leukemia. Rinsho Ketsueki. 2022;63(2):121-133. [Article in Japanese] doi: 10.11406/rinketsu.63.121